Federal grants to Fibrotherapeutics Inc
Fibrotherapeutics Inc in Charleston, South Carolina received $1.2 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Cardiovascular Diseases Research, with $606,402. It had no new grant money in fiscal 2025.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$1.2 million
- Awards4
- Awarded in FY 2025$0
- Largest award$337,740
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 2 | $559,531 |
| FY 2023 | 1 | $299,972 |
| FY 2024 | 2 | $344,240 |
| FY 2025 | 0 | $0 |
Programs that fund Fibrotherapeutics Inc
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 2 | $606,402 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 1 | $337,740 |
| Arthritis, Musculoskeletal and Skin Diseases Research | 1 | $259,601 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $1.2 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Novel therapeutic for kidney failure: a modified, water-soluble orally-active CAVEOLIN-1 scaffolding domain peptide with improved characteristics for drug development - abstract our long-term objective is to fill the unmet need for treatments for chronic kidney disease (CKD). CAVEOLIN-1 is a promisi | Diabetes, Digestive, and Kidney Diseases Extramural Research | August 7, 2024 | $337,740 |
| Novel therapeutics for heart failure: modified, water-soluble CAVEOLIN-1 scaffolding domain peptides with improved characteristics for drug development - abstract our long-term objective is to fill the unmet need for treatments for heart failure (HF). CAVEOLIN-1 is a promising therapeutic target in | Cardiovascular Diseases Research | February 8, 2023 | $306,472 |
| Novel therapeutics for interstitial lung disease: modified, water-soluble CAVEOLIN-1 scaffolding domain peptides with improved characteristics for drug development - abstract our long-term goal is to improve on the limited choices for treating the many devastating diseases that together constitute t | Cardiovascular Diseases Research | July 29, 2022 | $299,930 |
| Development of modified CAVEOLIN-1 scaffolding domain peptides with improved pharmacological properties as therapeutic agents for scleroderma skin disease - abstract our long-term objective is to develop an effective treatment for scleroderma (systemic sclerosis, ssc) skin fibrosis. CAVEOLIN-1 is a | Arthritis, Musculoskeletal and Skin Diseases Research | August 31, 2022 | $259,601 |
Questions people ask
How much federal grant money does Fibrotherapeutics Inc get?
$1.2 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Fibrotherapeutics Inc the most?
The Department of Health and Human Services, with $1.2 million in 4 awards.
What is Fibrotherapeutics Inc's largest federal grant?
$337,740 under Diabetes, Digestive, and Kidney Diseases Extramural Research, with its first action in the period on August 7, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Fibrotherapeutics Inc?
Its largest are Cardiovascular Diseases Research, Diabetes, Digestive, and Kidney Diseases Extramural Research and Arthritis, Musculoskeletal and Skin Diseases Research.
Other grant recipients in Charleston
- The Medical University of South Carolina
- Charleston, City of
- Charleston Area Regional Transportation Authority Inc
- Charleston County School District
- Housing Authority of City of Charles
- College of Charleston
- Trident Technical College
- One-Eighty Place
Largest federal grant recipients in South Carolina · Federal grants in South Carolina